ReviewChemical science2026
Less is more: miniaturized heme enzymes with broad reactivity.
Review in Chemical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heme enzymes are among the most efficient and versatile biocatalysts known, exploiting the rich redox chemistry of iron porphyrins to perform a wide range of transformations. Replicating and expanding this catalytic diversity within artificial systems remains a major challenge in bioinorganic chemistry. Among the strategies developed to design and engineer artificial heme enzymes, miniaturization occupies a distinctive position. Rather than reproducing the complexity of natural protein scaffolds, it builds on the structural knowledge of natural enzymes and works backward to identify the minimal peptide fragment that retains the essential information required for metal cofactor binding and catalytic function. Mimochromes (MCs) are among the most illustrative examples of this approach: a compact, synthetically accessible peptide scaffold surrounds a metalloporphyrin cofactor, providing a well-defined yet adaptable active site. This perspective outlines the design and development of MCs, from the early prototypes to the current benchmark catalyst MC6*a. Attention is devoted to the role of the MC scaffold in accommodating a broad range of substrates and modulating the reactivity of different metal ions. These features have enabled the development of first-in-class catalysts among both natural enzymes and artificial analogues, capable of promoting a remarkable variety of highly efficient and selective catalytic transformations spanning peroxidation and peroxygenation chemistry, electro- and photocatalytic hydrogen evolution, and electrocatalytic CO
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.